• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Short report: therapeutic efficacy of chloroquine combined with primaquine against Plasmodium falciparum in northeastern Papua, Indonesia.

作者信息

Baird J Kevin, Wiady Iwa, Sutanihardja Awalludin, Basri Hasan, Ayomi Ester, Fryauff David J, Hoffman Stephen L

机构信息

US Naval Medical Research Unit No 2, American Embassy Jakarta, Indonesia.

出版信息

Am J Trop Med Hyg. 2002 Jun;66(6):659-60. doi: 10.4269/ajtmh.2002.66.659.

DOI:10.4269/ajtmh.2002.66.659
PMID:12224570
Abstract

Chloroquine combined with primaquine was evaluated for therapy of uncomplicated malaria caused by Plasmodium falciparum in nonimmune Javanese migrants to northeastern Papua, Indonesia. Subjects were randomized to treatment with standard chloroquine therapy (25 mg/kg in 3 doses over the course of 48 hours) with 30 mg primaquine administered daily for 28 days (n = 25) or a placebo of primaquine (n = 28). The 14-day cumulative incidence of therapeutic failure was 56% with primaquine and 79% with placebo (odds ratio [OR], 0.35; 95% confidence interval [CI], 0.1-1.3; P = 0.08). Primaquine administered daily created a marginally significant improvement in therapeutic efficacy at day 14, but not at day 7 (20% versus 36%; OR, 0.2; 95% CI, 0.1-1.8; P = 0.2) or day 28 (82% versus 93%; OR, 0.31; 95% Cl, 0.04-2.1; P = 0.23). This report corroborates studies suggesting that therapeutic doses of primaquine exert no discernible effect on parasitemia by P. falciparum.

摘要

相似文献

1
Short report: therapeutic efficacy of chloroquine combined with primaquine against Plasmodium falciparum in northeastern Papua, Indonesia.
Am J Trop Med Hyg. 2002 Jun;66(6):659-60. doi: 10.4269/ajtmh.2002.66.659.
2
Halofantrine and primaquine for radical cure of malaria in Irian Jaya, Indonesia.卤泛群和伯氨喹用于印度尼西亚伊里安查亚疟疾的根治
Ann Trop Med Parasitol. 1997 Jan;91(1):7-16. doi: 10.1080/00034983.1997.11813106.
3
Malaria in a nonimmune population after extended chloroquine or primaquine prophylaxis.长期使用氯喹或伯氨喹预防后,非免疫人群中的疟疾。
Am J Trop Med Hyg. 1997 Feb;56(2):137-40. doi: 10.4269/ajtmh.1997.56.137.
4
Double-blind, randomized, placebo-controlled assessment of chloroquine/primaquine prophylaxis for malaria in nonimmune Colombian soldiers.氯喹/伯氨喹预防非免疫性哥伦比亚士兵疟疾的双盲、随机、安慰剂对照评估。
Clin Infect Dis. 1999 Jul;29(1):199-201. doi: 10.1086/520154.
5
Primaquine for prophylaxis against malaria among nonimmune transmigrants in Irian Jaya, Indonesia.伯氨喹用于印度尼西亚伊里安查亚非免疫移民疟疾预防。
Am J Trop Med Hyg. 1995 Jun;52(6):479-84. doi: 10.4269/ajtmh.1995.52.479.
6
Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua.在印度尼西亚巴布亚地区,氯喹治疗非复杂性恶性疟原虫和间日疟原虫疟疾的治疗失败风险非常高。
Am J Trop Med Hyg. 2003 Apr;68(4):416-20.
7
Chloroquine and primaquine: combining old drugs as a new weapon against falciparum malaria?氯喹和伯氨喹:将旧药组合成对抗恶性疟原虫疟疾的新武器?
Trends Parasitol. 2006 Jun;22(6):235-7. doi: 10.1016/j.pt.2006.03.006. Epub 2006 Apr 3.
8
Randomized, parallel placebo-controlled trial of primaquine for malaria prophylaxis in Papua, Indonesia.在印度尼西亚巴布亚进行的伯氨喹预防疟疾的随机、平行安慰剂对照试验。
Clin Infect Dis. 2001 Dec 15;33(12):1990-7. doi: 10.1086/324085. Epub 2001 Nov 12.
9
Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria.伯氨喹预防恶性疟和间日疟的随机安慰剂对照试验。
Lancet. 1995 Nov 4;346(8984):1190-3. doi: 10.1016/s0140-6736(95)92898-7.
10
Mefloquine is highly efficacious against chloroquine-resistant Plasmodium vivax malaria and Plasmodium falciparum malaria in Papua, Indonesia.甲氟喹对印度尼西亚巴布亚地区耐氯喹的间日疟原虫疟疾和恶性疟原虫疟疾具有高效。
Clin Infect Dis. 2006 Apr 15;42(8):1067-72. doi: 10.1086/501357. Epub 2006 Mar 13.

引用本文的文献

1
Drug resistance of Plasmodium falciparum and Plasmodium vivax isolates in Indonesia.印度尼西亚地区间恶性疟原虫和间日疟原虫分离株的耐药性。
Malar J. 2022 Nov 28;21(1):354. doi: 10.1186/s12936-022-04385-2.
2
Interactions of primaquine and chloroquine with PEGylated phosphatidylcholine liposomes.伯氨喹与聚乙二醇化磷脂酰胆碱脂质体的相互作用。
Sci Rep. 2021 Jun 14;11(1):12420. doi: 10.1038/s41598-021-91866-0.
3
Primaquine or other 8-aminoquinolines for reducing Plasmodium falciparum transmission.用于减少恶性疟原虫传播的伯氨喹或其他8-氨基喹啉类药物。
Cochrane Database Syst Rev. 2018 Feb 2;2(2):CD008152. doi: 10.1002/14651858.CD008152.pub5.
4
The blood schizonticidal activity of tafenoquine makes an essential contribution to its prophylactic efficacy in nonimmune subjects at the intended dose (200 mg).tafenoquine的血液裂殖体杀灭活性对其在非免疫人群中按预期剂量(200毫克)发挥预防效果起着至关重要的作用。
Malar J. 2017 May 19;16(1):209. doi: 10.1186/s12936-017-1862-4.
5
Cytochrome P450 2D-mediated metabolism is not necessary for tafenoquine and primaquine to eradicate the erythrocytic stages of Plasmodium berghei.对于他非诺喹和伯氨喹根除伯氏疟原虫红细胞内期而言,细胞色素P450 2D介导的代谢并非必需。
Malar J. 2016 Dec 7;15(1):588. doi: 10.1186/s12936-016-1632-8.
6
Primaquine or other 8-aminoquinoline for reducing Plasmodium falciparum transmission.伯氨喹或其他8-氨基喹啉用于减少恶性疟原虫传播。
Cochrane Database Syst Rev. 2015 Feb 19(2):CD008152. doi: 10.1002/14651858.CD008152.pub4.
7
Therapeutic responses of Plasmodium vivax malaria to chloroquine and primaquine treatment in northeastern Myanmar.缅甸东北部间日疟原虫疟疾对氯喹和伯氨喹治疗的反应
Antimicrob Agents Chemother. 2015 Feb;59(2):1230-5. doi: 10.1128/AAC.04270-14. Epub 2014 Dec 15.
8
Primaquine or other 8-aminoquinoline for reducing P. falciparum transmission.伯氨喹或其他8-氨基喹啉用于减少恶性疟原虫传播。
Cochrane Database Syst Rev. 2014 Jun 30(6):CD008152. doi: 10.1002/14651858.CD008152.pub3.
9
Cytostatic versus cytocidal profiling of quinoline drug combinations via modified fixed-ratio isobologram analysis.通过改良固定比例棋盘式分析研究喹啉类药物联合应用的细胞抑制与细胞杀伤作用。
Malar J. 2013 Sep 18;12:332. doi: 10.1186/1475-2875-12-332.
10
Prevention and treatment of vivax malaria.预防和治疗间日疟。
Curr Infect Dis Rep. 2007 Jan;9(1):39-46. doi: 10.1007/s11908-007-0021-4.